Experimental therapies for sepsis directed against tumour necrosis factor
Experimental therapies for sepsis directed against tumour necrosis factor
Tumour necrosis factor (TNF) has been identified as an important mediator involved in the generation of sepsis syndrome. Two major strategies have evolved for counteracting the effects of TNF in patients with severe manifestations of sepsis: neutralization by anti-TNF antibodies and competitive antagonism of TNF with synthetic soluble TNF receptors. Clinical trials with murine monoclonal antibodies against TNF have shown that this agent is able to reduce early morbidity and mortality, but with no reduction in 28 day mortality. A clinical study with a synthetic 75 kDa soluble TNF receptor failed to show any benefit with this drug and indeed there was higher mortality at higher doses. Trials of a 55 kDa soluble TNF receptor are continuing and this drug is apparently safe. Drugs that modify TNF in vivo may be a useful component of future management of sepsis, either as monotherapy or as part of a combined strategy of immunomodulation.
Antibodies, Monoclonal, Humans, Immunotherapy, Receptors, Tumor Necrosis Factor, Sepsis, Tumor Necrosis Factor-alpha, Journal Article, Review
65-69
Read, R.C.
b5caca7b-0063-438a-b703-7ecbb6fc2b51
January 1998
Read, R.C.
b5caca7b-0063-438a-b703-7ecbb6fc2b51
Read, R.C.
(1998)
Experimental therapies for sepsis directed against tumour necrosis factor.
Journal of Antimicrobial Chemotherapy, 41 (Suppl A), .
(doi:10.1093/jac/41.suppl_1.65).
Abstract
Tumour necrosis factor (TNF) has been identified as an important mediator involved in the generation of sepsis syndrome. Two major strategies have evolved for counteracting the effects of TNF in patients with severe manifestations of sepsis: neutralization by anti-TNF antibodies and competitive antagonism of TNF with synthetic soluble TNF receptors. Clinical trials with murine monoclonal antibodies against TNF have shown that this agent is able to reduce early morbidity and mortality, but with no reduction in 28 day mortality. A clinical study with a synthetic 75 kDa soluble TNF receptor failed to show any benefit with this drug and indeed there was higher mortality at higher doses. Trials of a 55 kDa soluble TNF receptor are continuing and this drug is apparently safe. Drugs that modify TNF in vivo may be a useful component of future management of sepsis, either as monotherapy or as part of a combined strategy of immunomodulation.
This record has no associated files available for download.
More information
Published date: January 1998
Keywords:
Antibodies, Monoclonal, Humans, Immunotherapy, Receptors, Tumor Necrosis Factor, Sepsis, Tumor Necrosis Factor-alpha, Journal Article, Review
Identifiers
Local EPrints ID: 417320
URI: http://eprints.soton.ac.uk/id/eprint/417320
ISSN: 0305-7453
PURE UUID: fd785e61-bc0f-4aa2-926b-28dee8d01edd
Catalogue record
Date deposited: 29 Jan 2018 17:30
Last modified: 16 Mar 2024 04:10
Export record
Altmetrics
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
